

Expression of H₁₁ Antigen (HABP) in Benign and Malignant Cervical Tumor Tissue Using mAb H₁₁B₂C₂

Manjunath S¹, Fekry B¹, Mortha KK¹

Abstract

Background: The development and progression of human tumors is accompanied by various cellular biochemical and genetic alterations. These events include tumor cells interaction with extracellular matrix molecules including hyaluronan and hyaluronan binding protein (HA-HAB). Hyaluronan is a large polysaccharide associated with pericellular matrix of proliferating, migrating cells, regulation of hyaluronan expression during cervical ripening. Its implication in malignant transformation, tumor progression and with the degree of differentiation in various invasive tumors has well accepted. It has been well known the role of HA receptors in tumor growth and metastasis in various cancer tissues.

Methods: The procedure carried out by using 10 benign and 30 different grades of cervical cancer tissue samples to see the expression of HABPs protein by western blotting method.

Results: This study is based on the clinical work of benign tissue and cervical cancer tissue samples. The results indicated that it is a HABP. It conforms that 57KD protein could be a common marker.

Conclusion: The HABP of 55-57KD and 30KD proteins, which were observed in western blot. It was shown by using a specific probe bHA for the detection of HABP, which recognizes all types of hyaladherins. Data suggests over-expression of H11 antigen (HABP) in tumor cells and it is an important parameter and a clinical diagnostic marker for all progressive human tumors.

Please cite this article as: Manjunath S, Fekry B, Mortha KK. Expression of H₁₁ Antigen (HABP) in Benign and Malignant Cervical Tumor Tissue Using mAb H₁₁B₂C₂. Iran J Cancer Prev, 2010 ; Vol3, No 2, p. 87-92.

Key Words: Hyaluronan (HA), H11 antigen, Hyaluronan-binding proteins (HABP), Cervical cancer, bHA (biotinylated hyaluronic acid)

1. Department of Biochemistry,
University of Mysore, Mysore-570
006, India

Corresponding Author:
Manjunath Siddaiah, M.Sc., PhD
Post Doctoral Scientist
Cancer Biology Lab
Tel: (+91)99-00 45 16 42
Email: ajaymanju2000@yahoo.co.in

Received: 3 Jan. 2010
Accepted: 20 Mar. 2010
IJCP 2010; 2: 87-92

Introduction

Hyaluronan (HA) is ubiquitously present in the extracellular matrices (ECMs) of animals, plays important roles in ECM organization and cell behavior through binding to hyaluronan-binding proteins (HABPs). The family of HA binding proteins are termed as hyaladherins [1], which include matrix HA-binding proteins and cell-surface HA receptors that exhibit high HA binding affinity. Extracellular hyaladherins include ECM proteins such as versican, aggrecan, neurocan, brevican, fibrinogen, hyaluronectin link protein and TSG-6 (tumor necrosis factor stimulated gene-6) and soluble protein such as α -trypsin inhibitor. Cellular hyaladherins include intracellular proteins such as CDC37, P32, RHAMM, HBP (hepatocyte binding protein) and IHABP4. Cellular receptors for the extracellular matrix component hyaluronan (HA) are involved in a broad

spectrum of biological processes i.e., organogenesis [2], development of embryonic structures [3], migration of normal cell [4] and activation of the immune response [5] and transmembrane proteins such as CD44 family (Eva Turley and Renu Harrison, RHAMM, a member of the hyaladherins). The extracellular hyaladherins, although present in smaller proportions, may participate in cartilage matrix assembly and maintenance of matrix integrity [6]. Cellular hyaladherins have been detected in several cell types from a wide variety of tissues [6, 7].

The diverse physiological functions of HA in cervical softening and ripening remain to be elucidated. In other cell systems, HA plays a structural role and mediates signaling events via interactions with cell surface receptors, such as RHAMM and CD44 [8]. CD44 and RHAMM are established signal-transducing receptors that

influence cell proliferation, survival and motility, and are known to be relevant to cancer. Other cell-surface hyaladherins, such as lymphatic-vessel endothelial hyaluronan receptor 1 (LYVE1) and TOLL4, might also have roles in cancer pathogenesis. Interactions of hyaluronan with CD44 and RHAMM lead to numerous cellular responses, including those that involve tyrosine kinases, protein kinase C, focal adhesion kinase (FAK), phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein kinase, nuclear factor- κ B and RAS as well as cytoskeletal components [8-11].

Thus the interactions of the extracellular matrix component hyaluronic acid and its cellular receptors CD44 and RHAMM/IHABP4/CDC37 have been linked to tumor progression and metastasis formation.

Both RHAMM and CD44 mediate hyaluronan signaling and participate in growth factor regulated signaling. However, they likely regulate signaling by different mechanisms because they are not homologous proteins and are compartmentalized differently in the cell and differ in the mechanisms by which they bind to hyaluronan. Additional cellular hyaladherins have been identified, but their role in cell signaling has not yet been reported. Therefore, this review focuses upon the signaling cascades that RHAMM and CD44 regulate.

It was observed the linear over-expression of H₁₁B₂C₂ antigen (HABP) by biochemical analysis in benign tumors, in various types of cancers including cervical tumors and also in different grades of cervical cancers.

Materials and Methods

Regular laboratory chemicals and reagents of analytical grade were purchased from Merck and Ranbaxy, India. Media and glasswares for mammalian cell culture were purchased from Gibco, BRL, Germany, Nunclon, Germany and Millipore, Germany. The secondary antibody was purchased from Genei, Bangalore, India.

Production of monoclonal antibody [mAb H₁₁B₂C₂]:

The antibody was originally produced by the fusion of a myeloma variant NS1 with splenic lymphocytes from SJL/J mice, immunized with semi-purified hyaluronic acid binding protein [12]. Hybridomas producing IVd4 antibody were selected, whose interaction with antigen was competed out by hyaluronic acid and hyaluronan oligomers [12]. Subsequent hybridomal clonal selections were performed by heat shock treatment, growing them in bovine serum and finally subcloned in filtered human serum of different blood groups received from the

hospitals. Furthermore the hybridoma was selected in HAT and HT media in DMEM. One of the clones H₁₁B₂C₂ was selected. The antibody production in human serum of any blood groups did not affect H₁₁B₂C₂ antibody in recognizing the human antigen expressed in tissues derived from malignant tumors. The clone H₁₁B₂C₂ were grown in DMEM containing 10% (v/v) human serum. After 14 days the media was collected. The media collected was taken and an equal volume of cold saturated ammonium sulphate solution was added with constant stirring at 4°C overnight and centrifuged at 12000rpm for 30min. The pellet was dissolved in PBS and dialyzed. After dialysis the antibody solution was lyophilized and antibody was dissolved in PBS whenever required.

Preparation of biotinylated hyaluronic acid (bHA):

Fifty (50) mg of hyaluronic acid was dissolved in 10ml of filtered PBS-A buffer (Ca and Mg free). The dissolved hyaluronan solution was dialyzed against 0.1M MES buffer PH 5.5 for 16hrs at 4°C. Later hyaluronan solution was mixed with 50mM Sulfo-NHS-LC-Biotin dissolved in DMSO, 50mM EDC for 16hrs at 4°C and then dialyzed against PBS-A for 36hrs at 4°C. Finally the dialyzed bHA was stored in glycerol at -20°C.

Extraction of protein from benign and malignant human tumor tissues:

Fresh tissues from benign and malignant cervical cancer samples were collected from the hospitals in cold PBS were stored at -20°C. Before extraction the samples were resuspended in lytic buffer and then homogenized (1:4w/v) in lysis buffer in a glass-Teflon homogenizer. The lysate was centrifuged at 10000rpm for 45min and an aliquot of the supernatant was assayed for protein concentration using Bradford method.

Detection of H₁₁ antigen in benign and malignant human tumor tissue using mAb H₁₁B₂C₂:

After extraction, equal amount of protein (50µg) from each of the tissue sample extract were taken and electrophoresed on a 10% SDS-PAGE [13] at 25mA constant current and electro transferred to a PVDF (Immobilon-p, Millipore) membrane at 200mA for 1hr at room temperature. Nonspecific binding was blocked with 5% non-fat dry milk and 1% BSA for 1hr at room temperature. The membrane was washed extensively with Tween-TBS buffer. The membrane was incubated with mAb H₁₁B₂C₂ (1:100 to 1:500 dilution) for 1hr at room temperature and overnight at 4°C. Next day the membrane was washed with Tween-TBS. The membrane was then

incubated with secondary antibody (goat anti mouse IgG biotin conjugated 1:1500 dilution) for 1hr at room temperature. The membrane was washed with Tween-TBS. The membrane was treated with HPO-9 (Strepta avidin peroxidase, Sigma 1:3000 dilution) for 1hr at room temperature. After extensive washing with Tween-TBS, the immuno-reactive proteins were visualized with ECL western blotting detection reagents (Pierce) or with DAB.

Detection of H11 antigens in benign and malignant human tumor tissue using a specific probe bHA:

After extraction, equal amount of protein (50µg) from each of the tissue sample extract were taken and electrophoresed on a 10% SDS-PAGE [13] at 25mA constant current and electro transferred to a PVDF (Immobilon-p, Millipore) membrane at 200mA for 1hr at room temperature. Nonspecific binding was blocked with 5% non-fat dry milk and 1% BSA for 1hr at room temperature. The membrane was washed extensively with Tween-TBS buffer. The membrane was incubated with B.HA (1:50 dilution) for 1hr at room temperature and overnight at 40C. Next day the membrane was washed with Tween-TBS. The membrane was treated with HPO-9 (1:3000 dilution) for 1hr at room temperature. After extensive washing with Tween-TBS, the immuno-reactive proteins were visualized with ECL western blotting detection reagents (Pierce) or with DAB.

Results

H11 antigen (HABP) expression by Western blot:

The expression of H11 antigen (HABP) as detected by mAbH11B2C2 was analyzed by western blotting method in different cancer tissues. They are also compared with benign cervical and cervical cancer tissues samples of different grades. Proteins were resolved in 10% SDS-PAGE. The benign samples screened for H11 antigen (HABP) are from chronic cervix and fibroadenoma. The cancer samples are from breast, rectum, cervix, colon, larynx, cheek, stomach, esophagus, tongue, pancreas, ovary, and cervix (G-I, II and III). Grade I, II and III are poorly differentiated, moderately differentiated and well differentiated cervical cancers respectively. The expression of two proteins of mol.wt 55-57 KD and 30KD was observed in all samples.

The H11 antigen (HABP) expression as detected by mAb H11B2C2 after western blotting from breast, ovary, rectum, cervix, colon and cheek cancer tissue samples was shown in (Fig1.1) The H11 antigen(HABP) expression as detected by mAb H11B2C2 after western blotting from larynx, stomach, esophagus, cervix, tongue and pancreas cancer tissue

samples was shown in (Fig1.2).The H11 antigen(HABP) expression as detected by mAb H11B2C2 after western blotting from stomach, larynx, esophagus, cervix (benign), cervix and fibroadenoma cancer tissue samples was shown in (Fig1.3).The cervical cancer shows strong expression and broad band's at 55- 57 KD and 30 KD. Compared to other cancer tissue samples. The H11 antigen (HABP) expression as shown in Figure1.1 and Figure1.2 were developed with DAB(Diamino benzidine hydrochloride) after western blotting, whereas, the H11 antigen(HABP) expression as shown in Figure 1.3 was developed with ECL(Enhanced chemiluminescence) after western blotting for higher sensitivity.

The H11 antigen(HABP) expression as detected by mAb H11B2C2 after western blotting in different grades of cervix, breast, colon and rectum cancer tissue samples was shown in Figure 1.4. A gradual increase in the expression of mAb H11B2C2 reactive H11 antigen (HABP) was observed from grade I to grade III of cervical cancer samples when developed with ECL for higher sensitivity.

Figure1.5 shows the H11 antigen expression in grade I and grade III cervical cancer tissue samples as detected by bHA when developed with ECL for higher sensitivity. They were compared with benign cervix samples. All the grades of cancer samples were showing strong reaction with bHA when compared with benign samples.

Figure 1.6 shows H11 antigen (HABP) expression in different samples of grade III cervical cancer tissue samples as detected by mAb H11B2C2 It shows strong expression and broad band at 55- 57 KD.

Figure 1.7 presents H11 antigen (HABP) expression in different grades of cervical cancer tissue samples and benign samples as detected by bHA. It shows gradual increase of H11 antigen (HABP) in different grades of cervical cancer tissue samples when compared with benign samples. This was developed with ECL for higher sensitivity.

The expression of H11 antigen in all grades III cervical cancer tissue samples as detected by bHA was given in Figure 1.8. All the samples showing very strong expression of H11 (HABP). The reaction was developed with ECL for higher sensitivity.

Among all the cancer tissues, cervical cancer tissue samples were selected to carry out the research program because it is the most common form of invasive carcinoma of cervix in women in developing countries and also the excessive availability of the cervical cancer tissues. It is the leading cause of cancer related deaths in women in the world in this tissue sample the H11B2C2 (HABP) expression was




Figure 1.1

H11 antigen expression in different cancers as detected by mAb H11B2C2 after western blotting. It was developed with DAB.

Lane 1: Breast Lane 2: Ovary
Lane 3: Rectum Lane 4: Cervix
Lane 5: Colon Lane 6: Cheek




Figure 1.2

H11 antigen expression in different cancers as detected by mAb H11B2C2 after western blotting. It was developed with DAB.

Lane 1: Larynx Lane 2: Stomach
Lane 3: Esophagus Lane 4: Cervix
Lane 5: Tongue Lane 6: Pancreas




Figure 1.3

H11 antigen expression in different cancers as detected by mAb H11B2C2 after western blotting. It was developed with ECL.

Lane 1: Stomach Lane 2: Larynx
Lane 3: Esophagus Lane 4: Cervix(Benign)
Lane 5: Cervix(Cancer) Lane 6: Fibroadenoma




Figure 1.4

H11 antigen expression in different grades of cervical cancer and also in different cancers as detected by mAb H11B2C2 after western blotting.

Lane 1: Cervix (Gr I) Lane 2: Cervix (GrII)
Lane 3: Cervix (Gr III) Lane 4: Breast
Lane 5: Rectum Lane 6: Colon

analyzed in different grades of cervical cancer tissue samples. There was a linear over-expression of H11B2C2 antigen (HABP) as the tumor progressed from G-I, G-II and G-III.

Discussion

In the present study an attempt has been made to elucidate the

mAbH₁₁B₂C₂-antigen affinity and expression in different types of benign and cancer tissue samples

by biochemical method. The study was also extended to different grades of cervical cancer tissues.

The importance of hyaluronan expression during tumor progression was investigated. It explains the positive association of stromal hyaluronan expression with invasive nature of tumors irrespective of their origin. The study explains the differential expression of hyaluronan in well differentiated tumors in contrast to the poorly differentiated [14]. The growing evidence of the presence of intracellular hyaluronan and its interaction with intracellular




Figure1.5

H11 antigen expression in different grades of cervical cancers and also in benign cervix as detected by bHA after western blotting

Lane 1: Cervical cancer (Grade I), Lane 2: Benign cervix
Lane 3: Cervical cancer (Grade III).




Figure1.6

H11 antigen expression by western blotting in different cancers as detected by bHA.

Lane 2: Cervical cancer (Gr I)
Lane 3: Cervical Cancer (Gr II)
Lane 4: Cervical cancer (Gr III)



Figure1.8

H11 antigen expression by western blotting in grade III of cervical cancers as detected by bHA

Lanes 1,2 and 3 : Grade III of cervical cancers

hyaladherins such as CDC37, IHABP4 [15,16] and further the subsequent loss of hyaluronan interaction with its receptor during late malignancy led to study the distribution of H₁₁ antigen (HABP) in multiple cancer tissues.

It was observed that human cervical cancer smears and paraffin tissues section of different types of cancers were screened by immunohistochemical technique for the presence of H₁₁ antigen (HABP). High expression of H₁₁ antigen (HABP) was seen in all human cervical cancer tissues. The distribution of H₁₁ antigen (HABP) is mainly on the tumor cell surface

and intracellular localization. The adjacent normal areas showed low expression of H₁₁ antigen (HABP).

Current study presented the nature of H₁₁B₂C₂ antibody and its affinity towards its antigen in different types of benign and cancer tissues. Western blot analysis indicated that H₁₁B₂C₂ antibody recognizes mainly two proteins of molecular weight 55-57KD and 30KD irrespective of the origin of tissue. The H₁₁ antigen (HABP) expression of molecular weight 55-57 and 30KD was seen in almost all types of cancer and by Scion Image Analysis it is evident. A significant increase in the H₁₁ antigen (HABP) expression was seen as the

tumor progressed from benign to malignant. The over expression of H₁₁ antigen(HABP) in the progression of malignant cervical tumor from well differentiated to poorly differentiated independent of their histological origin can be exploited, and is of significant value.

The 55-57KD and 30KD proteins, which were observed in western blot, probably a HABP. It was shown by using a specific probe bHA (biotinylated hyaluronic acid) for the detection of HABP, which recognizes all types of hyaladherins. The results indicated that it is a HABP. However further studies are necessary to show that 57KD protein could be a common marker. Activation of 57KD antigen may therefore represent a critical step in tumor progression and correspondingly may play an important role in the malignant transformation of human cells. Presently, limited information is available to provide the mechanism involved but the cumulative data suggests over-expression of H₁₁ antigen (HABP) in tumor cells and it is an important parameter and a clinical diagnostic marker for all progressive human tumors.

Acknowledgments

We would like to thank Dr. Shib das Banerjee, department of biochemistry, University of Mysore, Mysore for his critical Evolution of work. We would like to thank Dr.Geetha Avadhani, department of surgery K.R. hospitals, Mysore, India for providing benign and cancer tissue samples.

Conflict of Interest

The authors declare that they have no conflict of interest in this article.

Authors' Contribution

The biochemical experiments and writing the manuscript were done by all authors, while the biochemical studies were done by SM.

References

1. Toole B.P. Hyaluronan and its binding proteins, the hyaladherins. *Curr Opin Cell Biol* .1990; 2:839-44.
2. Fenderson B.A, Stamenkovic L, Aruffo A. Localization of hyaluronan in mouse embryos during implantation, gastrulation and organogenesis. *Differentiation*. 1993;54: 85-98.
3. Gakunga P, Frost G, Shuster S, Cunha G, Formby B, Stern R: Hyaluronan is a prerequisite for ductal branching morphogenesis. *J Development* 1997,124,3987 -3997.
4. Turley E.A. Hyaluronan and cell locomotion. *Cancer Metastasis Rev*. 1992; 11:21 -30.
5. DeGrendele HC, Estess P, Picker LJ, Siegelman MH. CD44 and its ligand hyaluronate mediate rolling under physiologic flow: A novel lymphocyte-endothelial cell primary adhesion pathway. *J Exp Med*. 1996; 183:1119-30.
6. Knudson C.B, Knudson W. Hyaluronan binding proteins in development, tissue homeostasis and disease. *FASEB J*.1993 ; 7- 1233-41.
7. Underhill C. CD44, The hyaluronan receptor. *J Cell Sci*. 1992;103:293-8
8. Turley E. A, Noble PW, Bourguignon L. Y. Signaling properties of hyaluronan receptors. *J. Biol. Chem*. 2002; 277:4589 -92.
9. Ponta H, Sherman L, Herrlich P. CD44: from adhesion molecules to signaling regulators. *Nature Rev Mol. Cell Biol*,2003 ; 4:33 -45.
10. Bourguignon L.Y. CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression. *J. Mammary Gland Biol Neoplasia*. 2001; 6,287 -97.
11. Thorne R. F, Legg J. W, Isacke C. M. The role of the CD44 transmembrane and cytoplasmic domains in coordinating adhesive and signalling events. *J. Cell Sci*, 2004; 117:373-80.
12. Banerjee S.D, Toole B.P .The determinants of migrating with a pre-arranged job and of the initial duration of urban unemployment: an analysis based on Indian data on rural-to-urban migrants. *J Dev Econ*. 1991; 36:337-51.
13. Laemmli UK. Cleavage of structural proteins during the assembly of the Head of bacteriophage T4. *Nature*. 1970; 227:680-5.
14. Boregowda Rajeev K, Hitesh N Appaiah, Manjunath Siddaiah, Sunil B Kumarswamy, Sunila Sunila, Thimmaiah KN, et al. Expression of Hyaluronan in human tumor progression. *J Carcinog*.2006;5:2 ,1477 -85.
15. Grammatikakis N, Grammatikakis A, Yoneda M, Yu Q, Banerjee SD , Toole BP. A novel glycosaminoglycan-binding protein is the vertebrate homologue of the cell cycle control protein Cdc37. *J Biol Chem* .1995; 270:16198-205.
16. Huang L, Grammatikakis N, Yoneda M, Banerjee SD , Toole BP. Molecular characterization of a novel intracellular hyaluronan- binding protein. *J Biol Chem* 2000; 275:29829 -39.